PT  - JOURNAL ARTICLE
AU  - Tang, Shan
AU  - Zhang, Jing
AU  - Mei, Ting-Ting
AU  - Guo, Hai-Qing
AU  - Wei, Xin-Huan
AU  - Zhang, Wen-Yan
AU  - Liu, Ya-Li
AU  - Liang, Shan
AU  - Fan, Zuo-Peng
AU  - Ma, Li-Xia
AU  - Lin, Wei
AU  - Liu, Yi-Rong
AU  - Qiu, Li-Xia
AU  - Yu, Hai-Bin
TI  - Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis
AID  - 10.1101/2020.05.19.20106385
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.19.20106385
4099  - http://medrxiv.org/content/early/2020/05/26/2020.05.19.20106385.short
4100  - http://medrxiv.org/content/early/2020/05/26/2020.05.19.20106385.full
AB  - Objective To systematically review the association of PNPLA3 rs738409 G/C gene polymorphism with non-alcoholic fatty liver disease(NAFLD) in children.Design Systematic review and meta-analysis.Data sources and study selection We searched MEDLINE, PubMed, EMBASE, and CENTRAL databases from inception to May 2019. Case-control studies assessing the relationship between PNPLA3 rs738409 G/C gene polymorphism with non-alcoholic fatty liver disease in children were selected according to inclusion and exclusion criteria.Data extraction and analyses First author’s surname, publication year, country, total numbers of patients in the case and control groups, sex ratio, and body mass index (BMI), as well as the numbers of cases and controls with the C/C, C/G and G/G genotypes were extracted from the included studies. Random effects model was used to quantify the association between the PNPLA3 rs738409 G/C gene polymorphism and the susceptibility of children’s NAFLD. Fixed effects model was used to quantify the relationship between the PNPLA3 rs738409 G/C gene polymorphism and the severity of NAFLD in children.Results A total of nine case-control studies were included in this meta-analysis containing data of 1173 children with NAFLD and 1792 healthy controls. Five studies compared NAFLD children and non-NAFLD healthy populations. Statistical analysis showed that PNPLA3 gene polymorphism was significantly associated with children’s NAFLD in the allele contrast, dominant, recessive and over dominant models (G vs C,OR=3.343, 95% CI=1.524-7.334; GG+GC vs CC,OR=3.157, 95% CI=1.446-6.892;GG vs GC+CC,OR=5.692, 95% CI=1.941-16.689; GG+CC vs GC,OR=2.756, 95% CI=1.729-4.392). Four case-control studies compared Children with nonalcoholic fatty liver (NAFL) and children with nonalcoholic steatohepatitis (NASH). The results showed that the PNPLA3 gene polymorphism was also significantly associated with the severity of NAFLD in children in recessive gene model(GG vs GC+CC,OR = 14.43, 95% CI = 5.985-34.997); The Egger’s test revealed no significant publication bias.Conclusions Meta-analysis showed that PNPLA3 gene polymorphism was significantly associated with susceptibility and severity of NAFLD in children.trial registration number: CRD42019134056.strengths and limitations of this study: 1.Published and previously unavailable data were synthesised to estimate the association of PNPLA3 rs738409 G/C gene polymorphism with NAFLD in children.2. This meta-analysis not only explored the relationship between PNPLA3 gene polymorphism and susceptibility of NAFLD in children, but also researched the relationship between PNPLA3 gene polymorphism and susceptibility of NASH in children. It can be further investigated whether PNPLA3 gene can be used to early diagnosis children NAFLD and evaluate the severity of NAFLD in children.3. High between-study heterogeneity and the likelihood of publication bias may impact the generalisability of our results.4. This meta-analysis only involved single factor studies, the interaction of PNPLA3 gene polymorphism and obesity,breastfeeding time were not taken into consideration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available.